Integer Holdings Co. (NYSE:ITGR) Sees Large Drop in Short Interest

Integer Holdings Co. (NYSE:ITGR - Get Free Report) saw a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 2,130,000 shares, a drop of 6.6% from the January 15th total of 2,280,000 shares. Approximately 6.6% of the shares of the company are short sold. Based on an average daily trading volume, of 212,300 shares, the short-interest ratio is presently 10.0 days.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ITGR shares. Citigroup raised their price target on Integer from $130.00 to $145.00 and gave the stock a "neutral" rating in a report on Wednesday, December 11th. Oppenheimer downgraded Integer from an "outperform" rating to a "market perform" rating in a research note on Friday. KeyCorp lifted their target price on Integer from $144.00 to $154.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Piper Sandler reiterated an "overweight" rating and set a $140.00 price target (up from $125.00) on shares of Integer in a research report on Friday, October 25th. Finally, Truist Financial lifted their target price on Integer from $147.00 to $163.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $147.67.

Integer Trading Down 3.9 %

NYSE:ITGR traded down $5.26 during trading hours on Friday, hitting $129.96. 499,342 shares of the stock were exchanged, compared to its average volume of 252,245. The company's 50 day moving average is $137.92 and its two-hundred day moving average is $132.31. Integer has a twelve month low of $98.63 and a twelve month high of $146.36. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $4.36 billion, a P/E ratio of 40.11, a price-to-earnings-growth ratio of 1.82 and a beta of 1.13.

Integer (NYSE:ITGR - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts' consensus estimates of $1.46 by ($0.03). The firm had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. On average, sell-side analysts anticipate that Integer will post 5.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integer

Several hedge funds have recently bought and sold shares of ITGR. Mather Group LLC. increased its stake in shares of Integer by 304.3% during the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 143 shares during the period. Lee Danner & Bass Inc. bought a new position in shares of Integer during the fourth quarter worth approximately $27,000. Huntington National Bank increased its stake in shares of Integer by 8,933.3% during the third quarter. Huntington National Bank now owns 271 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 268 shares during the period. R Squared Ltd bought a new position in shares of Integer during the fourth quarter worth approximately $44,000. Finally, Sterling Capital Management LLC increased its stake in Integer by 472.9% during the 4th quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 279 shares during the period. 99.29% of the stock is currently owned by institutional investors and hedge funds.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.